Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors

Pigment Cell and Melanoma Research

Volumn 27, Issue 3, 2014, Pages 479-484

  Basile, Kevin J ^a   Le, Kaitlyn ^a   Hartsough, Edward J ^a   Aplin, Andrew E ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

BRAF; Paradox breaker RAF inhibitor; Splice variant; Vemurafenib resistance

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; DABRAFENIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PLX 7904; SELUMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB; BRAF PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; ISOPROTEIN; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN; OXIME; PROTEIN KINASE INHIBITOR; RAF PROTEIN; SULFONAMIDE; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; G1 PHASE CELL CYCLE CHECKPOINT; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; MELANOMA; MOUSE; NONHUMAN; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; WILD TYPE; ANTAGONISTS AND INHIBITORS; CELL CYCLE; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; ENZYME ACTIVATION; ENZYMOLOGY; GENETICS; MISSENSE MUTATION; ONCOGENE RAS; PATHOLOGY; PHOSPHORYLATION; PROTEIN PROCESSING; TUMOR CELL LINE;

CELL CYCLE; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; GENES, RAS; GTP PHOSPHOHYDROLASES; HUMANS; IMIDAZOLES; INDOLES; MAP KINASE SIGNALING SYSTEM; MELANOMA; MEMBRANE PROTEINS; MUTATION, MISSENSE; NEOPLASM PROTEINS; OXIMES; PHOSPHORYLATION; PROTEIN ISOFORMS; PROTEIN KINASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS B-RAF; RAF KINASES; SIGNAL TRANSDUCTION; SULFONAMIDES; TUMOR STEM CELL ASSAY;

EID: 84898910552     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12218     Document Type: Article

References (21)

1. Basile, K.J., Abel, E.V., Dadpey, N., Hartsough, E.J., Fortina, P., and Aplin, A.E. (2013). In vivo MAPK reporting reveals the heterogeneity in tumoral selection of resistance to RAF inhibitors. Cancer Res. 73, 7101-7110.
2. Callahan, M.K., Rampal, R., Harding, J.J. et al. (2012). Progression of RAS-mutant leukemia during RAF inhibitor treatment. N. Engl. J. Med. 367, 2316-2321.
3. Chapman, P.B., Hauschild, A., Robert, C. et al. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516.
4. Chapman, P., Metz, D., Sepulveda, A. et al. (2012). Development of colonic adenomas and gastric polyps in BRAF mutant melanoma patients treated with vemurafenib. Pigment Cell Melanoma Res. 25, 847.
5. Choi, J., Landrette, S., Wang, T. et al. (2013). Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors. Pigment Cell Melanoma Res. 27, 254-63.
6. Flaherty, K.T., Puzanov, I., Kim, K.B. et al. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819.
7. Halaban, R., Zhang, W., Bacchiocchi, A., Cheng, E., Parisi, F., Ariyan, S., Krauthammer, M., Mccusker, J.P., Kluger, Y., and Sznol, M. (2010). PLX4032, a selective BRAF V600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF WT melanoma cells. Pigment Cell Melanoma Res. 23, 190-200.
8. Hauschild, A., Grob, J.J., Demidov, L.V. et al. (2012). Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380, 358-365.
9. Heidorn, S.J., Milagre, C., Whittaker, S. et al. (2010). Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221.
10. Hu, R., and Aplin, A.E. (2010). alphaB-crystallin is mutant B-RAF regulated and contributes to cyclin D1 turnover in melanocytic cells. Pigment Cell Melanoma Res. 23, 201-209.
11. Kaplan, F.M., Shao, Y., Mayberry, M.M., and Aplin, A.E. (2011). Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells. Oncogene 30, 366-371.
12. Kaplan, F.M., Kugel, C.H., Dadpey, N., Shao, Y., Abel, E.V., and Aplin, A.E. (2012). SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor. J. Biol. Chem. 287, 41797-41807.
13. Kim, K.B., Kefford, R., Pavlick, A.C. et al. (2013). Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J. Clin. Oncol. 31, 482-489.
14. Le, K., Blomain, E., Rodeck, U., and Aplin, A.E. (2013). Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells. Pigment Cell Melanoma Res. 26, 2155-2168.
15. Nazarian, R., Shi, H., Wang, Q. et al. (2010). Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973-977.
16. Oberholzer, P.A., Kee, D., Dziunycz, P. et al. (2012). RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated With RAF inhibitors. J. Clin. Oncol. 30, 316-321.
17. Poulikakos, P.I., Zhang, C., Bollag, G., Shokat, K.M., and Rosen, N. (2010). RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427-430.
18. Poulikakos, P.I., Persaud, Y., Janakiraman, M. et al. (2011). RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480, 387-390.
19. Shi, H., Moriceau, G., Kong, X. et al. (2012). Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat. Commun. 3, 724.
20. Sosman, J.A., Kim, K.B., Schuchter, L. et al. (2012). Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366, 707-714.
21. Su, F., Viros, A., Milagre, C. et al. (2012). RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med. 366, 207-215.